**Treatment Options for Colorectal Cancer Liver Metastases**

**Xianglong Tan**, **Mengyang Li** and **Zhiming Zhao**

1 The Second Department of Hepatopancreatobiliary Surgery, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, China
2 Department of Hepatopancreatobiliary Surgery, The Fourth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, China

**Abstract**

The liver is the most common site of metastasis in colorectal cancer (CRC). Treatment of liver metastases determines the prognosis of patients with CRC. Tremendous progress has been made during the last two decades, which has greatly improved the overall survival of CRC patients. Currently, various treatment options are available, including hepatectomy, liver transplantation, local regional therapy, chemotherapy, targeted therapy, and immune therapy, inevitably leading to some controversies on treatment indications and selection of treatment strategy. Here, we reviewed the existing approaches to treat colorectal cancer liver metastases, with the aim of examining several crucial questions regarding surgical resection, liver transplantation, and medical treatment in clinical practice.

**Introduction**

For patients with CRC, the liver is the most common site of metastasis. Approximately 15 percent of the CRC patients are initially diagnosed with liver metastasis, whereas 50% of the patients experience liver metastasis during the follow-up period. Treatment of liver metastasis determines the prognosis of the patients, and improvement in liver metastasis treatment can prolong the overall survival (OS) of CRC patients [1]. The 5-year survival rate of patients with resectable colorectal cancer liver metastases (CRLM) is 47%-60%, compared to 5%-9% in patients with unresectable CRLM [2-5]. With advances in chemotherapy and targeted therapy, an increasing number of unresectable metastatic lesions can be converted into resectable lesions. Additionally, hepatic artery infusion (HAI), associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), and two-stage hepatectomy (TSH) have also contributed to the increased resection rates and have improved the 5-year survival rate by 33%-50% after surgery [2, 6-8].

However, 60%-70% of these patients still develop hepatic tumor recurrence. Matsuoka et al. proposed an aggressive strategy of repeat hepatectomy to reduce chances of tumor recurrence and prolong OS [9]. Despite these strategies, there is still a large proportion of patients with unresectable CRLM. For patients without extrahepatic involvement, liver transplantation is a good option. For patients with multiple systematic metastases, including the liver, chemotherapy and targeted therapy are applied. Here, we summarize the various treatment options for CRLM patients.

**Surgical Resection**

Radical liver metastasis resection is the only treatment available for patients with CRLM. With improvements in chemotherapy, targeted drugs, and surgical techniques, an increasing number of patients can now undergo radical hepatectomy. The aim of liver resection is to remove all visible lesions and achieve a negative margin, leaving an adequate future liver remnant (FLR) [10]. Currently, about 20%-40% of cases of liver metastases are resectable [3, 11]. The 5- and 10-year OS rates are 47%-60% and 28%, respectively, whereas the 5- and 10-year disease-free survival rates are 30% and 20%, respectively [4, 12]. Age, comorbidity, lymph node metastasis, and extrahepatic tumor have been proven to be independent prognostic factors in CRLM patients [12]. Despite the decrease in adverse events over the last few decades, the complication rate is still relatively high (17% major complications and 26% minor...
complications) [13, 14]. Among the major complications, bleeding, bile duct injury, infection, liver abscess, and liver failure are most frequently encountered [10].

Although both laparoscopic and open hepatectomies are feasible, laparoscopic hepatectomy has been widely used in CRLM patients. Recently, the first explanatory, assessor-blinded, single-center, randomized superiority trial was performed by Fretland et al. to compare laparoscopic and open hepatectomy in CRLM resection. The results indicated that the complication rate was 19% in the laparoscopic group and 31% in the open resection group. A significant reduction in hospital stay was observed in the laparoscopic group, which was consistent with results obtained by Kasai et al. [15, 16]. No differences were observed between these two groups with respect to blood loss, operation time, surgical margin, and 90-day mortality [15]. In addition, there was no statistical difference in progression-free survival and OS [16].

Synchronous or metachronous resection has not reached an agreement. Approximately 15%-25% of CRC patients are diagnosed with liver metastases simultaneously. Historically, the median OS of patients with synchronous unresectable liver metastases was less than 8 months [17]. However, with the development of conversion chemotherapy and surgical techniques, 25% of CRLM patients who received synchronous resection may have a 10-year disease-free survival [18, 19]. The traditional surgical strategy is resection of the primary tumor, followed by a planned liver resection, which is known as the colon-first approach. Conversely, in the liver-first approach, liver resection is performed prior to colectomy. Metachronous resection helps to reduce complication rates. However, the tumor may progress during the interval period. Some studies have shown that compared to metachronous resection, synchronous resection leads to shorter hospital stays, lower costs, and less surgical trauma, without severely increasing mortality and morbidity [20, 21]. However, this may be a result of the different patient selection criteria used in the two approaches. Patients who undergo metachronous resection tend to have bilobar involvement or major hepatocarcinoma. There was no difference in long-term survival of patients who had synchronous or metachronous resection [21]. A meta-analysis reviewed 12 studies on laparoscopic versus open synchronous resection. No difference was observed between the two groups with respect to 1-, 3-, 5-year OS rates or disease-free survival rates. However, a significant reduction in postoperative complications was observed in the laparoscopic group (19% vs. 31%). The hospital stay was reduced after surgical resection in most of the studies [20].

Both ALPPS and TSH have their own advantages and drawbacks. Traditionally, TSH is preferred in patients with insufficient FLR. It involves chemotherapy with portal vein embolization or ligation followed by hepatectomy. However, this treatment is associated with a failure rate of 25%-38% due to insufficient hypotrophy or tumor progression [22-25]. A new surgical method, known as ALPPS, was developed in 2011 [26]. A recent meta-analysis showed that the kinetic growth rate was much higher with ALPPS than with TSH. Although ALPPS had higher morbidity and mortality compared to TSH, the OS rates were comparable between ALPPS and TSH [27]. Contradictory results were reported in another multicenter randomized controlled trial (LIGRO Trial). The resection rate of ALPPS was 92%, which was much higher than that obtained with traditional TSH (57%-75%). No difference in complications, 90-day mortality, or R0 resection rate was observed [25, 28].

HAI may be a good treatment strategy in some cases. It has known to improve the resection rate, palliative treatment, and enhance chemotherapy efficiency. A recent randomized controlled trial showed that treatment with HAI (fluorouracil, irinotecan and oxaliplatin) in combination with cetuximab for wild type KRAS multi-lesion metastases (median >10 lesions) showed a high response rate, and 30% of the patients achieved R0/R1 resection, despite some of them being resistant to previous systematic chemotherapy [2].

Although ALPPS, TSH, and HAI can increase the resection rate in CRLM, a large proportion of the patients still experience recurrence post resection. In these cases, repeat hepatectomy or systemic chemotherapy should be considered. A recent single-arm retrospective study in Japan showed that after initial hepatectomy, the median OS after single hepatectomy was 83.2 months, while patients who received two and three hepatectomies showed a median OS of 56.5 and 54.0 months, respectively. Conversely, in patients receiving palliative systematic chemotherapy, the median OS was only 28.7 months, thus indicating that repeat hepatectomy can improve the outcomes in patients [1]. Similar results were reported in several other studies [1, 29-31].

Liver Transplantation

CRLM is considered a contradiction for liver transplantation (LT). However, liver transplantation may provide a new prospect for CRLM treatment. Before the 1990s, there was no effective neoadjuvant chemotherapy and standard selection criteria, and the 5-year survival rate after LT in CRLM patients was less than 20%. However, the current 1-, 3-, 5-year survival rates have now increased to 83%-95%, 62%-68%, 50-60% respectively. Despite the encouraging results, recurrence occurs in 50%-90% of patients, either in the liver or in extrahepatic organs, such as the lungs [3].

In a pilot study (SECA trial), the OS of CRLM patients who received liver transplantation was investigated. In this trial, the patient selection criteria were as follows: complete radical excision of the primary tumor, good performance status (ECOG score 0 or 1), and a minimum 6 weeks of chemotherapy [32]. Under the guidance of these criteria, the SECA trial achieved excellent outcomes, with 1-, 3- and 5-year survival rates of 95%, 68%, and 60%, respectively [32]. A retrospective study compared the cohorts in the SECA trial and the NORDIC VII trial to evaluate the outcomes of liver transplantation versus chemotherapy. The former study enrolled 21 patients treated with liver transplantation, while the latter study enrolled 47 patients for chemotherapy only. The 5-year survival of the SECA cohort was 60% and that of the NORDIC VII trial cohort was only 9% [33].

Besides, negative lymph nodes in the primary tumor may be one of the criteria for CRLM patients to receive liver transplantation. The median survival of liver transplantation patients without lymph node metastases was 118 months, compared with 28 months in patients with lymph node metastases [3]. Prognosis factors related to worse OS are maximal tumor diameter above 5.5 cm, time from primary cancer surgery <2 years, CEA levels >80 μg/L, and progressive disease at the time of liver transplantation [32].

Surgical Case Reports doi: 10.31487/j.SCR.2020.04.04 Volume 3(4): 2-6
Radiofrequency Ablation (RFA)

Impaired general health status, insufficient FLR, and involvement of vital structures are contraindications for hepatectomy. Under these circumstances, chemotherapy and ablation are used [10, 34-37]. RFA is the most widely used ablation technique since the 1990s. The mortality rate is <1%, and the complication rate is 6%-9%, which is much lower than that of partial hepatectomy [10]. The 5-year survival rate in CRLM patients receiving RFA treatment is 25%-55%. Several observational studies have reported that RFA alone is inferior to hepatectomy alone, considering the OS [10]. However, RFA, in combination with partial hepatectomy for unresectable CRLM surprisingly had similar outcomes with partial hepatectomy for resectable CRLM patients [38, 39]. A recent study showed an impressive 8-year survival rate of 36% in unresectable CRLM patients who received RFA treatment [36].

Considering the results obtained from previous meta-analyses and reviews, randomized trials to estimate the outcome of RFA versus palliative chemotherapy for unresectable CRLM is unethical. Additionally, RFA, in combination with chemotherapy, is superior to chemotherapy alone. Bleeding, tumor seeding, liver abscess, and kidney failure are the main complications. The first prospective randomized controlled trial on thermal ablation versus chemotherapy for resectable CRLM is the COLLISION trial. If this trial proves that thermal ablation for <3 cm resectable CRLM is non-inferior to surgery, a reduction in the post-procedural morbidity and mortality, length of hospital stays, and incremental costs can be expected [10].

Chemotherapy and Target Drugs

Enormous progress has been made during the last two decades in CRLM chemotherapy. Currently, surgical resection combined with neoadjuvant and adjuvant chemotherapy is the standard treatment for CRLM patients. 5-Fluorouracil was used to be the only available chemotherapy regimen for CRLM before 1995, which showed a response rate of 20%-30%. Subsequently, the combination of 5-FU with oxaliplatin or irinotecan (FOLFOX and FOLFIRI) was used as the standard therapy with a better response rate (40%-60%) and R0 resection rate. Currently, FOLFOXIRI therapy, consisting of 5-FU, oxaliplatin, and irinotecan, is the best treatment of choice, with a 64% response rate and 87% R0 resection rate [18, 40, 41]. Genetic analysis has shown that a high proportion of CRLM patients have RAS mutations. Targeted therapies, such as anti-EGFR and anti-VEGF antibodies, may increase the response rate and prolong OS [2]. The anti-VEGF antibody, bevacizumab, is suggested for patients with RAS mutations in combination with first-line chemotherapy. The combination of anti-EGFR antibody, cetuximab, and chemotherapy is recommended for wild type RAS patients [2, 42, 43].

Perioperative chemotherapy for patients with initially resectable CRLM is controversial. Theoretically, perioperative chemotherapy can reduce the tumor size, ensuring R0 resection, and eliminate micro-metastases, thus reducing the recurrence rate [44]. However, perioperative chemotherapy (before and after surgery) showed modest improvement in PFS and no advantage in median OS, based on the results of a randomized controlled trial (the EORTC intergroup trial 40983). In addition, a higher complication rate was observed in the perioperative chemotherapy group [44-46]. For patients with initially unresectable CRLM, the response to preoperative chemotherapy should be estimated every 2 months [2]. Surgery can be performed 4 weeks after the last chemotherapy cycle, and 5-8 weeks later, for which chemotherapy plus bevacizumab was administered [47]. Surgery performed within 4 weeks was accompanied by a higher complication rate compared within 5-8 weeks [48, 49]. As mentioned above, liver resection is feasible in 20%-40% of CRLM patients. Receiving symptomatic therapy for unresectable CRLM patients provides a pessimistic median OS of only 4.5-12 months [50]. Systematic chemotherapy prolongs the median OS to 15-20 months [51].

KRAS mutations occur in 25%-52% of CRLM patients. A recent systematic review showed that KRAS mutations are correlated with worse OS and disease-free survival. KRAS wild-type CRLM patients have a median OS of more than 70 months, while patients with KRAS mutation had median OS from 19.6 to 50.9 months [52]. Patients with wtKRAS benefited from R0 resection of CRLM compared with R1 resection. However, patients with mutated KRAS are reported to have a higher R1 resection rate. Nevertheless, no prognostic difference was observed between R0 and R1 resection in these patients [53, 54]. In wild-type KRAS patients, an anti-EGFR regimen of cetuximab in combination with standard chemotherapy significantly improved the response rate, OS, and progression-free survival [55-57]. RAS mutations led to resistance to anti-EGFR antibodies. With the basic 5-FU treatment, patients with mutated KRAS treated with anti-VEGF antibody had an impaired response rate than wild-type patients with anti-EGFR antibody [58, 59]. Additionally, cetuximab combined with standard chemotherapy in wild-type KRAS patients improved the conversion resection rate, which was superior to bevacizumab in mutated KRAS patients [52].

BRAF mutation, which is detected in 3-11% CRLM patients, is strongly correlated with worse prognosis (mutBRAF 10.4 months vs. wtBRAF 34.7 months) [60]. As a member of the MAPK cascade, BRAF is downstream of KRAS. Mutations in BRAF also lead to anti-EGFR antibody resistance. Interestingly, microsatellite instability (MSI) is reported to have a much higher proportion of BRAF mutations (40%-60%) [61]. Immunotherapy may be a new option for BRAF-mutated patients. About 36-65.6% of CRLM patients are reported to have TP53 mutations. TP53 mutation, together with RAS mutation, is a strong indicator of worse prognosis, whereas TP53 mutation alone has no effect on OS and PFS [62-64]. Similarly, PIK3CA combined with APC mutation is correlated with impaired OS and PFS. PIK3CA alone was not associated with poor outcomes [65].

Immunotherapy

I. DC Vaccine

Patients who underwent hepatectomy have a high risk of recurrence. Rodriguez et al. reported that dendritic cell vaccines loaded with autologous tumor lysates can delay the recurrence in patients after receiving hepatectomy. The median disease-free survival in the vaccine arm was 25.26 months compared to 9.53 months in the observation arm [66].
II. Anti-PD-1 Regimen

The application of immune-checkpoints agents is not restricted to certain malignancies. The FDA previously approved anti-PD-1 regimens applied for MSI-H/dMMR solid tumors. Chromosomal instability (CIN), (MSI), and CpG island methylator phenotype (CIMP) are carcinogenic characteristics of CRC. MSI has been observed in 15% of CRC patients. Results from Checkmate-142 confirmed the effects of nivolumab + ipilimumab in patients with MSI-H/dMMR CRLM. The ORR was 64% and disease control was 84%. The 1-year progression-free survival was 50% and 1-year OS was 73% [67]. In the Keynote-164 study, pembrolizumab was used for the treatment of metastases of colorectal cancer and achieved an ORR of 26% and disease control rate of 51% [68, 69]. Studies combining PD-L1 inhibitors and bevacizumab have also been conducted. Hochster et al. presented their results from a phase 1b study. The combination has an ORR of 30%, with a DCR of 90% [70].

Conclusion

Surgery, local regional treatment, and medical therapies are the commonly used treatment strategies for patients with liver metastases. Among these, surgery is considered the only curative approach. Currently, indications for hepatectomy have expanded because of the advancements in ALPPS, TSH, HAI, and chemotherapy. Although liver transplantation is restricted by the availability of a suitable donor, it has indeed improved the possibility of curability or long-term survival of some patients with previously unresectable liver metastases. Chemotherapy is the foundation of metastatic malignancies. Better response rates and fewer side effects have been achieved during the last two decades. However, the timing of chemotherapy or surgery remains controversial. Based on gene sequencing, targeted therapy, together with immunotherapy, will continue to bring a new era for liver metastases treatment.

Conflicts of Interest

None.

Funding

None.

REFERENCES

1. Matsuoka H, Morise Z, Tanaka C, Hayashi T, Ikeda Y et al. (2019) Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer: a retrospective observational study. World J Surg Oncol 17: 33. [Crossref]
2. Adam R, Kitano Y (2019) Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg 3: 50-56. [Crossref]
3. Gorgen A, Muaddi H, Zhang W, McGilvray I, Gallinger S et al. (2018) The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol 2018: 9531925. [Crossref]
4. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N et al. (2012) The oncotherapy approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17: 1225-1239. [Crossref]
5. Siegel RL, Miller KD, Jemal A (2017) Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014. JAMA 318: 572-574. [Crossref]
6. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-657. [Crossref]
7. Adam R, Wicherts DA, de Haas RJ, Ciaccio O, Lévi F et al. (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27: 1829-1835. [Crossref]
8. Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ et al. (2012) A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19: 1292-1301. [Crossref]
9. Morise Z, Sugioa A, Fujita J, Hoshimoto S, Kato T et al. (2006) Does repeated surgery improve the prognosis of colorectal liver metastases? J Gastrointest Surg 10: 6-11. [Crossref]
10. Puijk RS, Ruurus AH, Vrooomen LGPH, van Tilborg AAJM, Scheffer HJ et al. (2018) Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 18: 821. [Crossref]
11. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J et al. (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254-259. [Crossref]
12. Acciuffi S, Meyer F, Bauschke A, Settmacher U, Lippert H et al. (2018) Analysis of prognostic factors after resection of solitary liver metastasis in colorectal cancer: a 22-year bicentre study. J Cancer Res Clin Oncol 144: 593-599. [Crossref]
13. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM et al. (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14: 56-61. [Crossref]
14. Dols LF, Verhofen C, Eksens FA, Schouten O, Nonner J et al. (2009) Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006. Ned Tijdscb Geneeskd 153: 490-495. [Crossref]
15. Fretland AA, Dagenborg VJ, Bjornelv GMW, Kazaryan AM, Kristiansen R et al. (2018) Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial. Ann Surg 267: 199-207. [Crossref]
16. Kasai M, Van Damme N, Berardi G, Geboes K, Laurent S et al. (2017) The inflammatory response to stress and angio genesis in liver resection for colorectal liver metastases: a randomized controlled trial comparing open versus laparoscopic approach. Acta Chir Belg 117: 172-180. [Crossref]
17. Wanebo HJ, Semoglou C, Attiyeh F, Stearns MJ Jr (1978) Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 135: 81-85. [Crossref]
18. Krell RW, D’Angelica MI (2019) Treatment sequencing for simultaneous colorectal liver metastases. J Surg Oncol 119: 583-593. [Crossref]
19. Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M et al. (2018) Actual 10-year survival after hepatic resection of colorectal liver
metastases: what factors preclude cure? Surgery 163: 1238-1244. [Crossref]
20. Moris D, Tsilimigras DI, Machairas N, Merath K, Cerullo M et al. (2019) Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. J Surg Oncol 119: 30-39. [Crossref]
21. Gavrilides P, Sutcliffe RP, Hodson J, Marudanayagam R, Isaacs J et al. (2018) Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis. HPB (Oxford) 20: 11-19. [Crossref]
22. Aussilhou B, Lesurtel M, Sauvanet A, Farges O, Dokmak S et al. (2008) Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant. J Gastrointest Surg 12: 297-303. [Crossref]
23. Capussotti L, Muratore A, Baracchi F, Lelong B, Ferrero A et al. (2008) Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg 143: 978-982. [Crossref]
24. Broering DC, Hillert C, Krupski C, Promadhat V, Mueller L et al. (2002) Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant. J Gastrointest Surg 6: 905-913. [Crossref]
25. Shindoh J, Truty MJ, Aloia TA, Curley SA, Zimmitti G et al. (2013) Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 216: 201-209. [Crossref]
26. Sandström P, Rosok BI, Sparrelid E, Larsen PN, Larsson AL et al. (2018) ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Ann Surg 267: 833-840. [Crossref]
27. Moris D, Ronnekleiv KN, Kostakis ID, Tsilimigras DI, Beal EW et al. (2018) Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. World J Surg 42: 806-815. [Crossref]
28. Adam R, Imai K, Castro Benitez C, Allard MA, Vibert E et al. (2016) Outcome after associating liver partition and portal vein ligation for staged hepatectomy and conventional two-stage hepatectomy for colorectal liver metastases. Br J Surg 103: 1521-1529. [Crossref]
29. Battula N, Tsapralis D, Mayer D, Issac J, Muijsean P et al. (2014) Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB (Oxford) 16: 157-163. [Crossref]
30. Navarro Freire F, Navarro Sanchez P, Miron Pozo B, Delgado Urena MT, Jimenez Rios JA et al. (2015) Recurrence of liver metastases from colorectal cancer and repeat liver resection. Rev Esp Enferm Dig 107: 732-739. [Crossref]
31. Andreou A, Brouquet A, Abdalla EK, Aloia TA, Curley SA et al. (2011) Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) 13: 774-782. [Crossref]
32. Hagness M, Fossa A, Line PD, Scholz T, Jorgensen PF et al. (2013) Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 257: 800-806. [Crossref]
33. Dueland S, Guren TK, Hagness M, Glimeilus B, Line PD et al. (2015) Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg 261: 956-960. [Crossref]
34. Belinson S, Chopra R, Yang Y, Shankaran V, Aronson N (2012) Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer [Internet] AHRQ Comparative Effectiveness Reviews. [Crossref]
35. Smith MD, McCall JL (2009) Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases. Br J Surg 96: 1101-1113. [Crossref]
36. Ruers T, Van Coevorden F, Punt CJ, Prieje ER, Borel Rinkes I et al. (2017) Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst 109. [Crossref]
37. Puijk RS, Ruuurs AH, Scheffer HJ, Vroonen LGPH, van Tilborg AAIM et al. (2018) Percutaneous Liver Tumour Ablation: Image Guidance, Endpoint Assessment, and Quality Control. Can Assoc Radiol J 69: 51-62. [Crossref]
38. Meijerink MR, Puijk RS, van Tilborg AAIM, Henningsen KH, Fernandez LG et al. (2018) Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol 41: 1189-1204. [Crossref]
39. Engstrand J, Nilsson H, Jansson A, Isaksun B, Freedman JE et al. (2014) A multiple microwave ablation strategy in patients with initially unresectable colorectal cancer liver metastases - A safety and feasibility study of a new concept. Eur J Surg Oncol 40: 1488-1493. [Crossref]
40. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegri G et al. (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676. [Crossref]
41. Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M et al. (2009) Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery 146: 52-59. [Crossref]
42. van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J et al. (2016) SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus SelectiveInternal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 34: 1723-1731. [Crossref]
43. Yoshino T, Uetake H, Tsuchihara K, Shiokara T, Yamaizaki K et al. (2017) Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS ) Wild-type, Metastatic Colorectal Cancer. Clin Colorectal Cancer 16: 158-163. [Crossref]
44. Chow FC, Chok KS (2019) Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol 11: 150-172. [Crossref]
45. Nordlinger B, Sobey H, Glimeilus B, Poston GJ, Schlag PM et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016. [Crossref]
46. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM et al. (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 14: 1208-1215. [CrossRef]

47. Nordlinger B, Vaanthe JN, Poston G, Benoist S, Rougier P et al. (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. *Clin Colorectal Cancer* 9: 212-218. [CrossRef]

48. Karoui M, Penna C, Amin Haschem M, Mitry E, Benoist S et al. (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. *Ann Surg* 243: 1-7. [CrossRef]

49. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M (2007) Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. *Br J Cancer* 96: 1037-1042. [CrossRef]

50. Bengmark S, Hafström L. (1969) The natural history of primary and secondary malignant tumors of the liver I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. *Cancer* 23: 198-202. [CrossRef]

51. Goldberg RM (2006) Therapy for metastatic colorectal cancer. *Oncologist* 11: 981-987. [CrossRef]

52. Tsilimigras DI, Ntanasis Stathopoulos I, Bagante F, Moris D, Cloyd J et al. (2018) Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. *Surg Oncol* 27: 280-288. [CrossRef]

53. Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE et al. (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. *Ann Surg Oncol* 23: 2635-2643. [CrossRef]

54. Margonis GA, Sasako K, Kim Y, Samah M, Buettnner S et al. (2016) Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. *J Gastrointest Surg* 20: 1821-1829. [CrossRef]

55. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX et al. (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. *J Clin Oncol* 31: 1931-1938. [CrossRef]

56. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 377: 2103-2114. [CrossRef]

57. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G et al. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol* 22: 1535-1546. [CrossRef]

58. Hatano E, Okuno M, Nakamura K, Ishii T, Seo S et al. (2015) Conversion to complete resection with nFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). *J Hepatobiliary Pancreat Sci* 22: 634-645. [CrossRef]

59. Galizia G, De Vita F, Lieto E, Zamboli A, Morgillo F et al. (2013) Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. *Oncol Rep* 30: 2992-2998. [CrossRef]

60. Barbon C, Margonis GA, Andreatos N, Rezaee N, Sasaki K et al. (2018) Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing? *J Gastrointest Surg* 22: 1286-1296. [CrossRef]

61. Tie J, Desai J (2015) Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. *Target Oncol* 10: 179-188. [CrossRef]

62. Chun YS, Passot G, Yamashita S, Nusret M, Katsonis P et al. (2019) Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. *Ann Surg* 269: 917-923. [CrossRef]

63. Frankel TL, Vakiani E, Nathan H, DeMatteo RP, Kingham TP et al. (2017) Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. *Cancer* 123: 568-575. [CrossRef]

64. Loes IM, Immervoll H, Sorbye H, Angelsen JH, Horn A et al. (2016) Impact of KRAS, BRAF, PIK3CA, TP53 status and individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. *Int J Cancer* 139: 647-656. [CrossRef]

65. Yamashita S, Chun YS, Kopetz SE, Maru D, Conrad C et al. (2017) APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. *Ann Surg* 4. [CrossRef]

66. Rodriguez J, Castaño E, Perez Gracia JL, Rodriguez I, Viudez A et al. (2018) A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. *J Immunother Cancer* 6: 96. [CrossRef]

67. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ et al. (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol* 18: 1182-1191. [CrossRef]

68. Emambugh S, Tachon G, Junca A, Tougeron D (2018) Results and challenges of immune checkpoint inhibitors in colorectal cancer. *Expert Opin Biol Ther* 18: 561-573. [CrossRef]

69. Le DT, Uram JN, Wan Y, Wride J, WUNDERLICH JR et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 372: 2509-2520. [CrossRef]

70. Hochster HS, Bendell JC, Cleave IM, Foster P, Zhang W et al. (2017) Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). *J Clin Oncol* 35: 673-673.